AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.
The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions.
The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease.
Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Country | United States |
IPO Date | Aug 4, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 56 |
CEO | David P. Hochman |
Contact Details
Address: 150 Union Square Drive New Hope, Pennsylvania United States | |
Website | https://orchestrabiomed.com |
Stock Details
Ticker Symbol | OBIO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001814114 |
CUSIP Number | 68572M106 |
ISIN Number | US68572M1062 |
Employer ID | 00-0000000 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
David P. Hochman | Founder, Chairman of the Board of Directors & Chief Executive Officer |
Andrew Lawrence Taylor M.B.A. | Chief Financial Officer |
Darren R. Sherman | Founder, President, Chief Operating Officer & Director |
Dr. Yuval Hay Mika D.Sc, Ph.D. | GM & Chief Technology Officer of Bioelectronic Therapies |
Bob Laughner | Senior Vice President of Regulatory & Quality |
Dr. Avraham Matityahu Fischer M.D. | Senior Vice President of Medical Affairs & Innovation |
Dr. George Papandreou Ph.D. | GM & Senior Vice President of Focal Therapies |
Dr. Hans-Peter Stoll M.D., Ph.D. | Chief Clinical Officer |
Juan Lorenzo | Senior Vice President of Product Development |
William Reed Little | Executive Vice President of Corporate Development & Strategy |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 30, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 20, 2024 | 4 | Filing |
Dec 19, 2024 | 4 | Filing |
Dec 13, 2024 | 4 | Filing |
Dec 06, 2024 | 4 | Filing |
Nov 12, 2024 | 10-Q | Quarterly Report |
Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Oct 23, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Sep 26, 2024 | 4 | Filing |